Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results
This proof-of-concept study demonstrates that targeting the IL-22 pathway with temtokibart is clinically effective with a favorable safety profile.
Authors
- Melinda Gooderham (ORCID: https://orcid.org/0000-0001-8926-0113)
- Charles W Lynde (ORCID: https://orcid.org/0000-0001-9163-5463)
- Vivian Laquer
- Petra Arlert
- Margitta Worm (ORCID: https://orcid.org/0000-0002-3449-1245)
- Martin Olesen
- Adam Reich (ORCID: https://orcid.org/0000-0002-5573-1754)
- Ole E. Sørensen (ORCID: https://orcid.org/0000-0001-8681-6921)
- Britta C. Martel
- Weily Soong (ORCID: https://orcid.org/0000-0002-2701-7035)
- Thomas Litman (ORCID: https://orcid.org/0000-0002-6068-901X)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
- Allan Blemings
Institutions
- University of Toronto (CA)
- Queen's University (CA)
- Orange Coast Memorial Medical Center (US)
- Lynde Centre for Dermatology (CA)
- Clinical Research Center for Hair and Skin Science (DE)
- Probity Medical Research (CA)
- West Coast Fertility Centers (US)
- Asthma Association (BG)
- Leo Pharma (Denmark) (DK)
- Charité - Universitätsmedizin Berlin (DE)
- University of Lübeck (DE)
- University of Rzeszów (PL)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1016/j.jaci.2025.08.034
- Citations
- 2
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.01